The new approach to cancer immunotherapy is expected to achieve increased efficacy compared to the method which Medinet has been providing.
In August 2007, both parties signed an exclusive license, development and supply agreement to use MaxCyte’s proprietary cell loading system to support clinical studies and commercialization of Medinet’s cancer immunotherapy service in Japan.
Under terms of the agreement, MaxCyte provides the exclusive right to utilize its proprietary technology in the closed-system manufacturing of Medinet’s immuno-cell therapy service in multiple cell processing centers across Japan.